Biomedical Engineering Reference
In-Depth Information
168. Curran, M. A.; Montalvo, W.; Yagita, H.; Allison, J. P. PD-1 and CTLA-4 Combination Block-
ade Expands Infiltrating T Cells and Reduces Regulatory T and Myeloid Cells Within B16
Melanoma Tumors.
Proc. Natl. Acad. Sci. U.S.A.
2010,
107,
4275-4280.
169. Elgueta, R.; Benson, M. J.; de Vries, V. C.; Wasiuk, A.; Guo, Y.; Noelle, R. J. Molecular
Mechanism and Function of CD40/CD40L Engagement in the Immune System.
Immunol.
Rev.
2009,
229,
152-173.
170. Carson, W. E.; Dierksheide, J. E.; Jabbour, S.; Anghelina, M.; Bouchard, P.; Ku, G., et al. Coad-
ministration of Interleukin-18 and Interleukin-12 Induces a Fatal Inflammatory Response in
Mice: Critical Role of Natural Killer Cell Interferon-gamma Production and STAT-mediated
Signal Transduction.
Blood
2000,
96,
1465-1473.
171. Phan, G. Q.; Yang, J. C.; Sherry, R. M.; Hwu, P.; Topalian, S. L.; Schwartzentruber, D. J.,
et al. Cancer Regression and Autoimmunity Induced by Cytotoxic T Lymphocyte-associated
Antigen 4 Blockade in Patients with Metastatic Melanoma.
Proc. Natl. Acad. Sci. U.S.A.
2003,
100,
8372-8377.
172. French, R. R.; Chan, H. T.; Tutt, A. L.; Glennie, M. J. CD40 Antibody Evokes a Cytotoxic
T-cell Response that Eradicates Lymphoma and Bypasses T-cell Help.
Nat. Med.
1999,
5,
548-553.
173. Sotomayor, E. M.; Borrello, I.; Tubb, E.; Rattis, F. M.; Bien, H.; Lu, Z., et al. Conversion
of Tumor-specific CD4+ T-cell Tolerance to T-cell Priming Through In vivo Ligation of
CD40.
Nat. Med.
1999,
5,
780-787.
174. Tutt, A. L.; O'Brien, L.; Hussain, A.; Crowther, G. R.; French, R. R.; Glennie, M. J. T Cell
Immunity to Lymphoma Following Treatment with Anti-CD40 Monoclonal Antibody.
J. Immunol.
2002,
168,
2720-2728.
175. van Mierlo, G. J.; den Boer, A. T.; Medema, J. P.; van der Voort, E. I.; Fransen, M. F.; Offringa,
R., et al. CD40 Stimulation Leads to Effective Therapy of CD40(−) Tumors Through Induc-
tion of Strong Systemic Cytotoxic T Lymphocyte Immunity.
Proc. Natl. Acad. Sci. U.S.A.
2002,
99,
5561-5566.
176. Nowak, A. K.; Robinson, B. W.; Lake, R. A. Synergy between Chemotherapy and Immu-
notherapy in the Treatment of Established Murine Solid Tumors.
Cancer Res.
2003,
63,
4490-4496.
177. Hamzah, J.; Nelson, D.; Moldenhauer, G.; Arnold, B.; Hammerling, G. J.; Ganss, r Vascular
Targeting of Anti-CD40 Antibodies and IL-2 into Autochthonous Tumors Enhances Immuno-
therapy in Mice.
J. Clin. Invest.
2008,
118,
1691-1699.
178. Vonderheide, R. H.; Flaherty, K. T.; Khalil, M.; Stumacher, M. S.; Bajor, D. L.; Hutnick, N. A.,
et al. Clinical Activity and Immune Modulation in Cancer Patients Treated with CP-870,893,
a Novel CD40 Agonist Monoclonal Antibody.
J. Clin. Oncol.
2007,
25,
876-883.
179. Ruter, J.; Antonia, S. J.; Burris, H. A.; Huhn, R. D.; Vonderheide, R. H. Immune Modula-
tion with Weekly Dosing of an Agonist CD40 Antibody in a Phase I Study of Patients with
Advanced Solid Tumors.
Cancer Biol. Ther.
2010,
10,
983-993.
180. Hussein, M.; Berenson, J. R.; Niesvizky, R.; Munshi, N.; Matous, J.; Sobecks, R., et al. A
Phase I Multidose Study of Dacetuzumab (SGN-40; Humanized anti-CD40 Monoclonal Anti-
body) in Patients with Multiple Myeloma.
Haematologica
2010,
95,
845-848.
181. Advani, R.; Forero-Torres, A.; Furman, R. R.; Rosenblatt, J. D.; Younes, A.; Ren, H., et al.
Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refrac-
tory or Recurrent Non-Hodgkin's Lymphoma.
J. Clin. Oncol.
2009,
27,
4371-4377.
182. Kimura, K.; Moriwaki, H.; Nagaki, M.; Saio, M.; Nakamoto, Y.; Naito, M., et al. Pathogenic
Role of B cells in Anti-CD40-induced Necroinflammatory Liver Disease.
Am. J. Pathol.
2006,
168,
786-795.
